Uncategorized
Ocuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops
FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced today that it has successfully enrolled 39 glaucoma patients in ORION-1 at 5 U.S. sites from late May to August 2019. The objectives of the randomized, placebo-controlled, double-masked study of once daily 1% Nyxol in subjects with open angle glaucoma or ocular hy